Midatech Divests US Unit To Focus On Its Rival Drug To Novartis' Sandostatin LAR

 
• By Sten Stovall

UK-based Midatech will use money from its US divestment to ramp up R&D efforts and progress its key oncology product MTD201, which has a favorable clinical profile versus Novartis' blockbuster Sandostatin LAR, the biotech's CEO tells Scrip.

R&D
UK Biotech Selling US Affiliate To Raise Money For Pipeline Advancement • Source: Shutterstock

More from Strategy

More from Business